ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NAKA
LFMD (32) AIRS (33) BMGL (53) ALPS (52) ⌘ Pro Terminal →

Nakamoto Inc. (NAKA) — RQD Stock Rating Cockpit

$5.54 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.48

Nakamoto Inc. (NAKA) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $107.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NAKA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NAKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nakamoto Inc. (NASDAQ: NAKA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $5.54 (-5.46% 1D, market cap $107.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NAKA ranks #1002 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NAKA compare to LFMD and AIRS in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), NAKA carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.6%. By comparison, LFMD (LifeMD Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.2%, cap $110.4M) and AIRS (AirSculpt Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.0%, cap $124.7M). Among the 5-stock peer group, NAKA leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NAKA?
▼

Per NAKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946573), Nakamoto Inc. generated $1.8M in revenue (-33.0% YoY), -$52.2M in net income, and -$23.5M in free cash flow against $730.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.48 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510018
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (3)SEC (5)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-18.1% Base Target
$39 Bull$5 Base$4 Bear
📬 FREE NAKA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAKA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY NAKA SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$8.58-16.8% Next Q
Q2 (-2Q)
23
Grade E$7.14+0.3% Next Q
Q3 (-1Q)
21
Grade E$7.16-22.6% Next Q
Current
18
Grade E$5.54-12.2% Hist 90D α
Trajectory: E (26) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NAKA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NAKA currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.18) and Max Pain ($5.82) forces dealer call-delta covering toward $38.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAKA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NAKA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
37.730 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE7% OF RANGE
L: $3$5.54H: $37
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 9 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NAKA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-31.6% ROIC with 42.0% gross margin and -18.63% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (18)

6/40 institutional & smart-money positioning score with 4/20 macro alignment.

Bull Case: Why Buyers Like NAKA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAKA)

  • ✓Walkthrough of NAKA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NAKA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.49%📐 HORIZONTAL RANGE
2026-11-03O $6.88H $6.88L $5.54C $5.54VOL 295.1K
RES: $11.20SUP: $0.31SMA50: $8.18SMA200: $7.86
$90.57$66.92$43.28$19.64$-4.01RES $11.20SUP $0.31$5.542026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAKA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAKA Butterfly Map → + Track NAKA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -33.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NAKA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAKA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAKA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAKA)

Health Care Rank #1002 of 1015 ⚔️ LFMD vs NAKA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAKA vs. LFMD, AIRS, BMGL, ALPS)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nakamoto Inc. (NAKA) ranks #1002 by composite RQD confidence (18/100, grade E) and #642 by equity capitalization ($107.5M). Within this direct 5-issuer industry benchmark cohort, NAKA leads on earnings valuation at N/A trailing P/E, while AIRS leads on capital efficiency and profitability with -7.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with NAKA at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NAKA ACTIVE
Nakamoto Inc.
E 18/100 — — -31.6% -5.46% $107.5M Benchmark Subject
LFMD
LifeMD Inc.
E 32/100 — 85.7% -26.2% +0.87% $110.4M /lfmd-vs-naka →
AIRS
AirSculpt Technologies Inc.
E 33/100 — — -7.0% -3.47% $124.7M /airs-vs-naka →
BMGL
Basel Medical Group Ltd
D+ 53/100 — — — +1.39% $68.5M /bmgl-vs-naka →
ALPS
ALPS Group Inc Ordinary Share
D+ 52/100 — — — -0.21% $54.1M /alps-vs-naka →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001946573 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nakamoto Inc. (NAKA) reported GAAP revenue of $1.8M (-33.0% vs. FY2024 revenue of $2.7M , and -51.7% cumulative change since FY2023) , GAAP net income of -$52.2M, operating cash flow of -$23.5M, and free cash flow of -$23.5M (-661.6% YoY). On the balance sheet, NAKA closed FY2025 with $730.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.8M -$52.2M -$23.5M -$23.5M $730.6M —
FY2024 (FY) 2024-12-31 $2.7M -$3.6M -$3.1M -$3.1M $3.7M —
FY2023 (FY) 2023-12-31 $3.8M -$1.6M -$449.5K -$449.5K — —

3. NAKA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nakamoto Inc. (NASDAQ: NAKA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $5.54 (-5.46% 1D, market cap $107.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NAKA ranks #1002 in composite RQD confidence.

How does NAKA compare to LFMD and AIRS in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), NAKA carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.6%. By comparison, LFMD (LifeMD Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.2%, cap $110.4M) and AIRS (AirSculpt Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.0%, cap $124.7M). Among the 5-stock peer group, NAKA leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NAKA?

Per NAKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946573), Nakamoto Inc. generated $1.8M in revenue (-33.0% YoY), -$52.2M in net income, and -$23.5M in free cash flow against $730.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NAKA trading relative to its 50-day, 200-day, and 52-week technical levels?

NAKA last traded at $5.54 (-5.46% on volume of 254,557 shares), positioning the stock -32.27% below its 50-day simple moving average ($8.18) and -29.52% below its 200-day simple moving average ($7.86). Across its 52-week range of $3.33 to $36.80, NAKA sits at the 6.6% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.85 to $6.23).

Direct Sub-Reports: NAKA RQD Cockpit NAKA 12M Forecast NAKA Earnings & Move NAKA Dividends & DRIP NAKA Insiders & 13F NAKA Whale Options NAKA Profit Sankey NAKA News & Why
ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

NAKA — Nakamoto Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nakamoto Inc. (NAKA) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.54 (-5.46% 1D, market capitalization $107.5M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -31.6%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -18.63%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Nursing Services industry. The reported revenue figures are shown in the Financial Trend section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nakamoto Inc. (NAKA) reported $1.8M in annual revenue (up from $2.7M in FY2024, -33.0% YoY) and -$52.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.8M revenue, -$1.6M net income) through FY2025, NAKA scaled operating cash flow to -$23.5M and free cash flow to -$23.5M, backed by $730.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -18.63% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.33 – $36.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish dependencies on suppliers, customers, or peer companies. Sector-level context is limited to the Health Care classification.

  • Key Question #1: Can NAKA sustain or expand its -60.0% operating margin and -31.6% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.8M and free cash flow of -$23.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NAKA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NAKA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nakamoto Inc. (NAKA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NAKA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NAKA Bull vs. Bear Conversation Board — What's Your Call at $5.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NAKA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NAKA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $7.62 (+30.0%)
📌 Pinned Debate

The Bitcoin-related all-stock acquisitions and the reported 18.28 percent price spike could be catalysts for a re-rating if the transac

Here is why I am bullish on NAKA here at $5.86: The Bitcoin-related all-stock acquisitions and the reported 18.28 percent price spike could be catalysts for a re-rating if the transactions improve the business.. Compare NAKA's -60.0% operating margin and -31.6% ROIC against the rest of Medical/Nursing Services. As long as cash conversion holds up, dips toward $5.57 are getting bought.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $5.86 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.63 (-21.0%)
Spot @ $5.86

With an Altman Z-Score of 0.2, a Piotroski F-Score of 2/9, and an FY 2025 operating loss of -$197.1M, the company shows severe forensic

With an Altman Z-Score of 0.2, a Piotroski F-Score of 2/9, and an FY 2025 operating loss of -$197.1M, the company shows severe forensic and cash-burn risk.. Look at the math on NAKA: paying current EV/EBITDA multiples for -31.6% ROIC and -60.0% operating margins leaves zero margin of safety if Medical/Nursing Services demand softens. I'd wait for a retest of $5.16 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%